Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 3
Submit an article Journal homepage
103
Views
19
CrossRef citations to date
0
Altmetric
Drug Evaluation

Long-term use of sildenafil

Culley C Carson University of North Carolina School of Medicine, Chapel Hill, NC 27599-7000, USA
Pages 397-405 | Published online: 02 Mar 2005

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Edgardo Becher. (2004) Topical alprostadil cream for the treatment of erectile dysfunction. Expert Opinion on Pharmacotherapy 5:3, pages 623-632.
Read now

Articles from other publishers (18)

Stephen M. Stahl. 2021. Prescriber's Guide. Prescriber's Guide 729 732 .
Stephen M. Stahl. 2021. Prescriber's Guide. Prescriber's Guide.
Jong Nyeong Kim, Jong Jin Oh, Dong Soo Park, Young Kwon Hong & Young Dong Yu. (2019) Influence of Alcohol on Phosphodiesterase 5 inhibitors Use in Middle- to Old-Aged Men: A Comparative Study of Adverse Events. Sexual Medicine 7:4, pages 425-432.
Crossref
Claudia Miranda, Zenia Pérez-Rodríguez, Rosario Hernández-Armengol, Yaidel Quiñones-García, Tania Betancourt-Purón & Miguel Ángel Cabrera-Pérez. (2018) Biowaiver or Bioequivalence: Ambiguity in Sildenafil Citrate BCS Classification. AAPS PharmSciTech 19:4, pages 1693-1698.
Crossref
Mary Lee. (2011) Focus on Phosphodiesterase Inhibitors for the Treatment of Erectile Dysfunction in Older Men. Clinical Therapeutics 33:11, pages 1590-1608.
Crossref
Giuseppe Lombardi, Angelo Macchiarella, Filippo Cecconi & Giulio Del Popolo. (2009) Ten‐Year Follow‐Up of Sildenafil Use in Spinal Cord‐Injured Patients with Erectile Dysfunction. The Journal of Sexual Medicine 6:12, pages 3449-3457.
Crossref
Culley C. CarsonIIIIII. (2007) Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class. Urologic Clinics of North America 34:4, pages 507-515.
Crossref
Mohammed A. Osman, Gamal M. El Maghraby & Mohsen A. Hedaya. (2006) Intestinal absorption and presystemic disposition of sildenafil citrate in the rabbit: evidence for site-dependent absorptive clearance. Biopharmaceutics & Drug Disposition 27:2, pages 93-102.
Crossref
Dolores Vernet, Thomas Magee, Ansha Qian, Gaby Nolazco, Jacob Rajfer & Nestor Gonzalez‐Cadavid. (2006) Phosphodiesterase Type 5 Is Not Upregulated by Tadalafil in Cultures of Human Penile Cells. The Journal of Sexual Medicine 3:1, pages 84-95.
Crossref
Juan B. Salom, María C. Burguete, Fernando J. Pérez-Asensio, María Castelló-Ruiz, Germán Torregrosa & Enrique Alborch. (2006) Relaxant effect of sildenafil in the rabbit basilar artery. Vascular Pharmacology 44:1, pages 10-16.
Crossref
A. FABBRI & A. AVERSA. (2005) The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs. International Journal of Andrology 28:s2, pages 69-73.
Crossref
Riadh Daghfous, Sihem El Aidli, Ahmed Zaiem, Mohamed Hedi Loueslati & Chelbi Belkahia. (2005) Sildenafil-Associated Hepatotoxicity. The American Journal of Gastroenterology 100:8, pages 1895-1896.
Crossref
Culley C. Carson & Tom F. Lue. (2005) Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU International 96:3, pages 257-280.
Crossref
Matthias LükeChristoph LükeJürgen HeschelerToni SchneiderWerner Sickel. (2005) Effects of Phosphodiesterase Type 5 Inhibitor Sildenafil on Retinal Function in Isolated Superfused Retina. Journal of Ocular Pharmacology and Therapeutics 21:4, pages 305-314.
Crossref
Francesco Montorsi, Louis Kuritzky, Richard Sadovsky, Paul Fredlund & William H. Cordell. (2005) Frequently asked questions about tadalafil for treating men with erectile dysfunction. The Journal of Men's Health & Gender 2:1, pages 141-157.
Crossref
Clive Gingell, Stefan R. Sultana, Maria B. Wulff & Sam Gepi‐Attee. (2004) Duration of Action of Sildenafil Citrate in Men with Erectile Dysfunction. The Journal of Sexual Medicine 1:2, pages 179-184.
Crossref
Culley C. CarsonIIIIII. 2004. Sildenafil. Sildenafil 35 47 .
Culley C. CarsonIIIIII. (2003) Sildenafil: A 4-year update in the treatment of 20 million erectile dysfunction patients. Current Urology Reports 4:6, pages 488-496.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.